candesartan has been researched along with Cardiotoxicity in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | 9.41 | Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "The findings do not support the hypothesis that concomitant use of candesartan protects against a decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer." | 9.22 | Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. ( Altena, R; Boekhout, AH; de Boer, J; de Vries, EG; Gietema, JA; Honkoop, A; Kema, IP; Kessels, L; Los, M; Mandigers, CM; Milojkovic Kerklaan, B; Nieboer, P; Ottevanger, PB; Schellens, JH; Smilde, T; Smit, WM; Smorenburg, CH; van der Velden, AW; van der Wouw, AJ; van Veldhuisen, DJ; van Werkhoven, ED, 2016) |
| " Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomized to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone." | 5.69 | Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. ( Borley, A; Broom, A; Collins, G; Eddie, L; Everett, RJ; Fletcher, A; Guppy, A; Hall, P; Henriksen, PA; Japp, A; Joshi, SS; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Primrose, L; Radford, J; Rodriguez, A; Rowntree, C; Singh, T; Stavert, H; Williams, MC, 2023) |
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | 5.41 | Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA) was a 2 × 2 factorial, placebo-controlled, double-blinded trial of candesartan and metoprolol." | 5.27 | Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. ( Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2018) |
| "The findings do not support the hypothesis that concomitant use of candesartan protects against a decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer." | 5.22 | Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. ( Altena, R; Boekhout, AH; de Boer, J; de Vries, EG; Gietema, JA; Honkoop, A; Kema, IP; Kessels, L; Los, M; Mandigers, CM; Milojkovic Kerklaan, B; Nieboer, P; Ottevanger, PB; Schellens, JH; Smilde, T; Smit, WM; Smorenburg, CH; van der Velden, AW; van der Wouw, AJ; van Veldhuisen, DJ; van Werkhoven, ED, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Majhi, S | 1 |
| Singh, L | 1 |
| Yasir, M | 1 |
| Henriksen, PA | 1 |
| Hall, P | 1 |
| MacPherson, IR | 1 |
| Joshi, SS | 1 |
| Singh, T | 1 |
| Maclean, M | 1 |
| Lewis, S | 1 |
| Rodriguez, A | 1 |
| Fletcher, A | 1 |
| Everett, RJ | 1 |
| Stavert, H | 1 |
| Broom, A | 1 |
| Eddie, L | 1 |
| Primrose, L | 1 |
| McVicars, H | 1 |
| McKay, P | 1 |
| Borley, A | 1 |
| Rowntree, C | 1 |
| Lord, S | 1 |
| Collins, G | 1 |
| Radford, J | 1 |
| Guppy, A | 1 |
| Williams, MC | 1 |
| Japp, A | 1 |
| Payne, JR | 1 |
| Newby, DE | 1 |
| Mills, NL | 1 |
| Oikonomidou, O | 1 |
| Lang, NN | 1 |
| Lee, M | 1 |
| Chung, WB | 1 |
| Lee, JE | 1 |
| Park, CS | 1 |
| Park, WC | 1 |
| Song, BJ | 1 |
| Youn, HJ | 1 |
| Heck, SL | 1 |
| Gulati, G | 1 |
| Hoffmann, P | 1 |
| von Knobelsdorff-Brenkenhoff, F | 1 |
| Storås, TH | 1 |
| Ree, AH | 1 |
| Gravdehaug, B | 1 |
| Røsjø, H | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Schulz-Menger, J | 1 |
| Omland, T | 1 |
| Higa, A | 1 |
| Hoshi, H | 1 |
| Yanagisawa, Y | 1 |
| Ito, E | 1 |
| Morisawa, G | 1 |
| Imai, JI | 1 |
| Watanabe, S | 1 |
| Takagi, M | 1 |
| Boekhout, AH | 1 |
| Gietema, JA | 1 |
| Milojkovic Kerklaan, B | 1 |
| van Werkhoven, ED | 1 |
| Altena, R | 1 |
| Honkoop, A | 1 |
| Los, M | 1 |
| Smit, WM | 1 |
| Nieboer, P | 1 |
| Smorenburg, CH | 1 |
| Mandigers, CM | 1 |
| van der Wouw, AJ | 1 |
| Kessels, L | 1 |
| van der Velden, AW | 1 |
| Ottevanger, PB | 1 |
| Smilde, T | 1 |
| de Boer, J | 1 |
| van Veldhuisen, DJ | 1 |
| Kema, IP | 1 |
| de Vries, EG | 1 |
| Schellens, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab[NCT00459771] | Phase 3 | 210 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for candesartan and Cardiotoxicity
| Article | Year |
|---|---|
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Topics: Adrenergic beta-Antagonists; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardioto | 2023 |
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antibiotics, Antineoplastic; Antihype | 2021 |
Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bipheny | 2018 |
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antineoplast | 2016 |
2 other studies available for candesartan and Cardiotoxicity
| Article | Year |
|---|---|
Evaluation of Ameliorative Effect of Quercetin and Candesartan in Doxorubicin-Induced Cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiomyopathies; Cardiotoxicity; Doxorubicin; H | 2022 |
Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.
Topics: Amlodipine; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Cardiotoxicity; Ce | 2017 |